NCT03709017View on ClinicalTrials.gov

Iclusig PMS in CML or Ph+ALL Patients

UnknownOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

August 7, 2018

Primary Completion Date

November 29, 2022

Study Completion Date

June 30, 2023

Conditions
Chronic Myeloid LeukemiaPhiladelphia Chromosome-positive Acute Lymphoblastic Leukemia
Interventions
DRUG

Ponatinib

Iclusig 45mg, 15mg

Trial Locations (1)

Unknown

Kosin University Gaspel Hospital, Busan

Sponsors
All Listed Sponsors
lead

Korea Otsuka Pharmaceutical Co., Ltd.

INDUSTRY